Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Dicerna Pharmaceutic (NQ: DRNA )

24.64 USD UNCHANGED
Streaming Delayed Price Updated: 5:01 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Dicerna Pharmaceutic

< Previous 1 2 3 4 5 6 7 8 9 Next >
PBE's Holdings Imply 11% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
First Week of DRNA February 2021 Options Trading
Investors in Dicerna Pharmaceuticals Inc (DRNA) saw new options become available this week, for the February 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the... 
Tags Stocks
From Market News Video
Stocks Generating Improved Relative Strength: Dicerna Pharmaceuticals
Dicerna Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
Notable Friday Option Activity: MAXR, DRNA, OPCH
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Maxar Technologies Inc (MAXR), where a total volume of 5,451 contracts has been... 
Tags Stocks
From Market News Video
Dicerna Pharmaceuticals Trying To Close In On Key Technical Benchmark
Dicerna Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market. The ... 
Tags DRNA PRPO General
From Benzinga
Analysts Anticipate ESML Will Reach $33
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags CTMX ARNA TBPH
From Benzinga
The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings
Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and ... 
Tags CTLT JAZZ RTRX
From Benzinga
IBD Rating Upgrades: Dicerna Pharmaceuticals Shows Improved Relative Price Strength
A Relative Strength Rating upgrade for Dicerna Pharmaceuticals shows improving technical performance. Will it continue? 
From Investor's Business Daily
Dicerna Pharmaceuticals (DRNA) Shares Cross Above 200 DMA
In trading on Thursday, shares of Dicerna Pharmaceuticals Inc (DRNA) crossed above their 200 day moving average of $20.51, changing hands as high as $20.74 per share. Dicerna Pharmaceuticals Inc shares... 
Tags Stocks
From Market News Video
Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment
Shares of Vertex plunged after hours Wednesday after the company announced it planned to stop testing on a drug designed to treat protein deficiencies. VRTX stock fell by double digits. 
From Investor's Business Daily
Noteworthy Thursday Option Activity: X, UNH, DRNA
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in United States Steel Corp. (X), where a total volume of 59,397 contracts has been... 
Tags Stocks
From Market News Video
Implied PBE Analyst Target Price: $75
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Interesting DRNA Put And Call Options For November 20th
Investors in Dicerna Pharmaceuticals Inc (DRNA) saw new options become available this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the... 
Tags Stocks
From Market News Video
Top Buys by Top Brass: CEO Fambrough's $180.6K Bet on DRNA
A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider... 
Tags Stocks
From Market News Video
Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps
Arrowhead Pharma posted positive clinical trials data on a promising drug to treat a rare genetic liver disease, and ARWR stock soared near a nine-moth high; shares of rival Dicerna also jumped. 
From Investor's Business Daily
Grab This Bargain Even Cheaper Than CEO Fambrough Did
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on September 1, Dicerna Pharmaceuticals Inc's CEO, Douglas... 
Tags Stocks
From Market News Video
Friday 9/4 Insider Buying Report: RGT, DRNA
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their... 
Tags Stocks
From Market News Video
Stocks With Rising Relative Strength: Dicerna Pharmaceuticals
A Relative Strength Rating upgrade for Dicerna Pharmaceuticals shows improving technical performance. Will it continue? 
From Investor's Business Daily
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) ABIOMED, Inc. (NASDAQ: ABMD) Aerpio Pharmaceuticals Inc ... 
Tags IPOs ACHV SPRO
From Benzinga
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical ... 
Tags PEN BCRX PACB
From Benzinga
2 Stocks to Hold for the Next 20 Years
Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span. 
Tags DRNA FATE JNJ
From Motley Fool
Interesting DRNA Put And Call Options For September 18th
Investors in Dicerna Pharmaceuticals Inc (DRNA) saw new options begin trading this week, for the September 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the... 
Tags Stocks
From Market News Video
Sum Up The Pieces: FYC Could Be Worth $46
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Dicerna Pharmaceuticals Shows Rising Price Performance With Jump To 91 RS Rating
Dicerna Pharmaceuticals sees its Relative Strength Rating hit the elite 90-plus level. 
From Investor's Business Daily
Dicerna Pharmaceuticals Moves Up In Market Cap Rank, Passing Under Armour
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Dicerna Pharmaceuticals Inc (DRNA) was identified as having a larger market cap than the smaller end of the... 
Tags Stocks
From Market News Video
2 Top Small-Cap Stocks to Buy Right Now
Volatile stock market or not, these two drug developers are well positioned for long-term success. 
Tags CHRS PFE AMGN
From Motley Fool
Is Arrowhead Pharmaceuticals a Buy?
The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress. 
Tags LLY ALXN JNJ
From Motley Fool
Is Alnylam Pharmaceuticals a Buy?
The stock is up an amazing 2,100% since the company went public, stomping the S&P 500. 
Tags Market News ALNY NVS
From Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.